Mersana’s innovative platforms have enabled us to build a pipeline for both Mersana and our collaborators. Our ADCs in preclinical studies and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need.
We believe our platforms create an opportunity for ADCs with improved safety and efficacy relative to those developed using first-generation technology.

Platform	ADC Program	Target	Indication	Discovery	Preclinical	P1 Dose Escalation	P1 Dose Expansion
G1
Dolasynthen	XMT-1660	B7-H4	Multiple Solid Tumors
G2
Immunosynthen	XMT-2056*	Novel HER2 Epitope	Multiple Solid Tumors
Immunosynthen	XMT-2068	Undisclosed	Undisclosed
Immunosynthen	XMT-2175	Undisclosed	Undisclosed
Collaborations
Collaborations:
Dolasynthen		Multiple	Undisclosed
Immunosynthen		Multiple	Undisclosed
Dolaflexin		Multiple	Undisclosed
Dolaflexin		5T4	Undisclosed

Platform	ADC Program	Target	Indication	Phase
Dolasynthen	XMT-1660	B7-H4	Multiple Solid Tumors	P1 Dose Escalation
Immunosynthen	XMT-2056*	Novel HER2 Epitope	Multiple Solid Tumors	P1 Dose Escalation
	XMT-2068	Undisclosed	Undisclosed	Discovery
	XMT-2175	Undisclosed	Undisclosed	Discovery
Collaborators:
Immunosynthen		Multiple	Undisclosed	Discovery
Dolasynthen		Multiple	Undisclosed	Discovery
Dolaflexin		Multiple	Undisclosed	Preclinical
Dolaflexin		5T4	Undisclosed	P1 Dose Escalation

^*XMT-2056 is wholly owned by Mersana, with GSK having an exclusive global license option to co-develop and commercialize the candidate.